Go to
current issue
-
The Pandemic Agreement is a milestone: now it is time for action in national capitals Lancet (IF 98.4) Pub Date : 2025-06-03
Helen Clark, Ellen Johnson SirleafNo Abstract
-
Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial Lancet (IF 98.4) Pub Date : 2025-06-02
Alexander B Olawaiye, Laurence Gladieff, David M O'Malley, Jae-Weon Kim, Gabriel Garbaos, Vanda Salutari, Lucy Gilbert, Linda Mileshkin, Alix Devaux, Elizabeth Hopp, Yong Jae Lee, Ana Oaknin, Mariana Scaranti, Byoung-Gie Kim, Nicoletta Colombo, Michael E McCollum, Connie Diakos, Andrew Clamp, Aliza L Leiser, Boglárka Balázs, Domenica LorussoBackgroundRelacorilant, a first-in-class selective glucocorticoid receptor antagonist, increases a tumour's sensitivity to chemotherapy by reducing cortisol signalling. This study aimed to show whether the addition of relacorilant to nab-paclitaxel improves progression-free and overall survival in females with platinum-resistant ovarian cancer. MethodsThis randomised, controlled, open-label phase 3
-
Sudan's tuberculosis response needs global support amid conflict Lancet (IF 98.4) Pub Date : 2025-06-02
Ahmad Mohammad Al Zamel, Ali Awadallah Saeed, Mazin Elmubarak, Mohamed Abdulmonem AlsarrajNo Abstract
-
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial Lancet (IF 98.4) Pub Date : 2025-06-02
Luis Paz-Ares, Hossein Borghaei, Stephen V Liu, Solange Peters, Roy S Herbst, Katarzyna Stencel, Margarita Majem, Mehmet Ali Nahit Şendur, Grzegorz Czyżewicz, Reyes Bernabé Caro, Ki Hyeong Lee, Melissa L Johnson, Nuri Karadurmuş, Christian Grohé, Sofia Baka, Tibor Csőszi, Jin Seok Ahn, Raffaele Califano, Tsung-Ying Yang, Yasemin Kemal, Martin ReckBackgroundDespite improved efficacy with first-line immune checkpoint inhibitors plus platinum-based chemotherapy for extensive-stage small-cell lung cancer (ES-SCLC), survival remains poor. In this study, we aimed to compare lurbinectedin plus atezolizumab and atezolizumab alone as maintenance therapies in patients with ES-SCLC without progression after induction therapy with atezolizumab, carboplatin
-
Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study Lancet (IF 98.4) Pub Date : 2025-06-02
Alice P Chen, Geraldine O'Sullivan Coyne, Pamela L Wolters, Staci Martin, Said Farschtschi, Ignacio Blanco, Zhongping Chen, Luiz Guilherme Darrigo, Marica Eoli, James R Whittle, Yoshihiro Nishida, Rosa Lamarca, Randolph de la Rosa Rodriguez, Ayo Adeyemi, Idoia Herrero, Nereida Llorente, Scott J Diede, Eva Dombi, Pierre Wolkenstein, Yoshimasa NobeyamaBackgroundCurrently, no worldwide approved therapies exist for adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas. The KOMET study aimed to evaluate selumetinib (ARRY-142886, AZD6244) efficacy and safety in this population. MethodsThis ongoing multicentre, international, randomised, placebo-controlled, phase 3, parallel, double-blind trial randomly assigned
-
Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial Lancet (IF 98.4) Pub Date : 2025-05-31
Changsong Qi, Chang Liu, Zhi Peng, Yanqiao Zhang, Jia Wei, Wensheng Qiu, Xiaotian Zhang, Hongming Pan, Zuoxing Niu, Meng Qiu, Yanru Qin, Weijia Fang, Feng Ye, Ning Li, Tianshu Liu, Anwen Liu, Xizhi Zhang, Changlu Hu, Jun Zhang, Jiuwei Cui, Lin ShenBackgroundClaudin-18 isoform 2 (CLDN18.2) has emerged as a promising therapeutic target in gastric or gastro-oesophageal junction cancer. Satricabtagene autoleucel (satri-cel; also known as CT041), an autologous CLDN18.2-specific chimeric antigen receptor (CAR) T-cell therapy, showed encouraging activity in previously treated patients with advanced gastric or gastro-oesophageal junction cancer in phase
-
Seeking an inclusive and just way to simplify the global health architecture Lancet (IF 98.4) Pub Date : 2025-05-29
Michel Kazatchkine, Jon LidénNo Abstract
-
Testicular cancer Lancet (IF 98.4) Pub Date : 2025-05-29
Julian Chavarriaga, Lucia Nappi, Alexandros Papachristofilou, Ciara Conduit, Robert J HamiltonTesticular cancer is the most common solid malignancy in people with testicles aged 15–44 years, accounting for 1–2% of all tumours in males of all ages. Approximately 95% of testicular cancers are testicular germ cell tumours. This Seminar focuses on testicular cancer, with an emphasis on testicular germ cell tumours. We delve into the epidemiology, clinical presentation, disease management, controversies
-
Department of Error Lancet (IF 98.4) Pub Date : 2025-05-29
Paris L, Al-Jadba G, Zeidan W, et al. Deterioration of health outcomes in Gaza: 19 months of protracted conflict. Lancet 2025; published online May 22. https://doi.org/10.1016/S0140-6736(25)00812-8—In this Correspondence, the European Centre for Disease Prevention and Control affiliation should have read “ECDC Fellowship Programme, Field Epidemiology path (EPIET), European Centre for Disease Prevention
-
Safety of low-intensity monitoring after thrombolysis in acute ischaemic stroke Lancet (IF 98.4) Pub Date : 2025-05-29
Susan AshcraftNo Abstract
-
Janabi elected as new WHO Regional Director for Africa Lancet (IF 98.4) Pub Date : 2025-05-29
Paul AdepojuNo Abstract
-
WHA adopts new strategy on traditional medicine Lancet (IF 98.4) Pub Date : 2025-05-29
Talha BurkiNo Abstract
-
-
Moving from evidence to prioritised action on AMR Lancet (IF 98.4) Pub Date : 2025-05-29
Dominic Moran, Clare I R Chandler, Steven Montgomery Laird, Benjamin J Parcell, Laura A Richards, Julie RobothamNo Abstract
-
Implementation challenges of personalised phage therapy Lancet (IF 98.4) Pub Date : 2025-05-29
Sarah Djebara, Rob Lavigne, Jean-Paul PirnayNo Abstract
-
Prioritising maternal health must include care before pregnancy Lancet (IF 98.4) Pub Date : 2025-05-29
Danielle Schoenaker, Judith Stephenson, Sanhita Chakrabarti, Lara Alloway, Keith M GodfreyNo Abstract
-
Critical factors for improving maternal health Lancet (IF 98.4) Pub Date : 2025-05-29
Mary J Renfrew, Leslie Altic, Chris Gale, Alexander Heazell, Marian KnightNo Abstract
-
Global trends and projections in antimicrobial resistance Lancet (IF 98.4) Pub Date : 2025-05-29
Manica BalasegaramNo Abstract
-
Global trends and projections in antimicrobial resistance Lancet (IF 98.4) Pub Date : 2025-05-29
Edmond Siu-Keung Ma, Shuk-Ching Wong, Vincent Chi-Chung Cheng, Peng WuNo Abstract
-
Global trends and projections in antimicrobial resistance Lancet (IF 98.4) Pub Date : 2025-05-29
Abebaw Fekadu, Yimtubezinash Woldeamanuel, Asrat Hailu, Eyasu MakonnenNo Abstract
-
Global trends and projections in antimicrobial resistance Lancet (IF 98.4) Pub Date : 2025-05-29
Sylvia Yang Liu, Zhuowei Long, Song Lin ChuaNo Abstract
-
Global trends and projections in antimicrobial resistance Lancet (IF 98.4) Pub Date : 2025-05-29
Vimalraj Selvaraj, Swathi Sudhakar, Saravanan SekaranNo Abstract
-
Global trends and projections in antimicrobial resistance – Authors' reply Lancet (IF 98.4) Pub Date : 2025-05-29
Tomislav Mestrovic, Rebecca Hsu, Lucien Swetschinski, Christopher J L Murray, Mohsen NaghaviNo Abstract
-
-
The need to strengthen the US Food and Drug Administration: US cuts threaten health care at home and abroad Lancet (IF 98.4) Pub Date : 2025-05-28
Jayasree K IyerNo Abstract
-
Zackie Achmat: irrepressible health activist Lancet (IF 98.4) Pub Date : 2025-05-27
Sarah BoseleyNo Abstract
-
-
Special issue on neurology: call for papers Lancet (IF 98.4) Pub Date : 2025-05-27
Beatriz Gomez Perez-Nievas, Helen Frankish, Richard HortonNo Abstract
-
Transcatheter aortic valve implantation: lessons from the ACURATE IDE trial Lancet (IF 98.4) Pub Date : 2025-05-23
Stephan Windecker, Thomas PilgrimNo Abstract
-
Retraction—Taiwan's national health care on the brink of systemic collapse Lancet (IF 98.4) Pub Date : 2025-05-23
Jing-Xing Li, Shu-Bai HsuIn this Correspondence,1 we identified several inaccuracies in the presentation of information and references, which may mislead readers and not truly reflect the current situation of the national health-care system in Taiwan. In our commitment to upholding the highest standards of academic integrity, we respectfully request the retraction of this Correspondence. This experience has prompted serious
-
Health and faith partnerships to strengthen trust: the Georgetown–Lancet Commission on Faith, Trust, and Health Lancet (IF 98.4) Pub Date : 2025-05-22
Deus Bazira, Kezevino Aram, David Beasley, Oliver Johnson, Jack Leslie, Katherine Marshall, John Monahan, Amna Qayyum, Olivia WilkinsonNo Abstract
-
Emily Mendenhall: applying anthropological thinking to medicine Lancet (IF 98.4) Pub Date : 2025-05-22
Aarathi PrasadNo Abstract
-
Jacifusen for FUS-ALS: molecular effects and clinical outcomes in a case series Lancet (IF 98.4) Pub Date : 2025-05-22
Naoki Suzuki, Ayumi Nishiyama, Satoru Ebihara, Masashi AokiNo Abstract
-
Antisense oligonucleotide jacifusen for FUS-ALS: an investigator-initiated, multicentre, open-label case series Lancet (IF 98.4) Pub Date : 2025-05-22
Neil A Shneider, Matthew B Harms, Vlad A Korobeynikov, Olivia M Rifai, Benjamin N Hoover, Elizabeth A Harrington, Sonya Aziz-Zaman, Jessica Singleton, Arish Jamil, Vikram R Madan, Ikjae Lee, Jinsy A Andrews, Richard M Smiley, Mahabub M Alam, Lauren E Black, Minwook Shin, Jonathan K Watts, David Walk, Daniel Newman, Robert M Pascuzzi, C Frank BennettBackgroundPathogenic variants of fused in sarcoma (FUS) cause amyotrophic lateral sclerosis (FUS-ALS), with evidence of gain of function. Jacifusen is an antisense oligonucleotide targeting FUS pre-mRNA, previously shown to delay neurodegeneration in a mouse model and potentially slow functional decline in a first-in-human study. Here, we sought to further evaluate use of jacifusen as a treatment for
-
-
-
The final 20 years of the Gates Foundation Lancet (IF 98.4) Pub Date : 2025-05-22
Udani SamarasekeraNo Abstract
-
Logistics of the malaria vaccine roll-out in Nigeria Lancet (IF 98.4) Pub Date : 2025-05-22
Ahmad Olawale Atere, Fatihi Bamigbola Mustapha, Mubarak Jolayemi MustaphaNo Abstract
-
Decentralising clinical trial access requires a culture of health equity Lancet (IF 98.4) Pub Date : 2025-05-22
Sabe Sabesan, Craig Underhill, Ramya Thota, Stephen Sundquist, Tolulope AdewoleNo Abstract
-
Department of Error Lancet (IF 98.4) Pub Date : 2025-05-22
Early Breast Cancer Trialists’ Collaborative Group. Reductions in recurrence in women with early breast cancer entering clinical trials between 1990 and 2009: a pooled analysis of 155 746 women in 151 trials. Lancet 2024; 404: 1407–18—In figure 1 of this Article, the number excluded from the 148 092 women with oestrogen receptor-positive disease should read 33 281. This correction has been made as
-
Trachoma Lancet (IF 98.4) Pub Date : 2025-05-22
Esmael Habtamu, Emma M Harding-Esch, Katie Greenland, Teyil Wamyil-Mshelia, Sandra L Talero, Sailesh Kumar Mishra, Thomas M Lietman, Anthony W Solomon, Matthew J BurtonTrachoma, the leading infectious cause of blindness worldwide, is one of several neglected tropical diseases targeted by WHO for elimination by 2030. The disease starts in childhood with repeated episodes of conjunctival Chlamydia trachomatis infection. This infection is associated with recurrent conjunctivitis (active trachoma), which, if left untreated, leads to cicatricial trachoma characterised
-
Announcing The Lancet Commission on Disability and Health: Creating disability-inclusive health systems that leave no one behind Lancet (IF 98.4) Pub Date : 2025-05-21
Hannah Kuper, Tom Shakespeare, Winnie Mpanju-ShumbushoNo Abstract
-
Accelerating progress on essential medicines: a new Lancet Commission Lancet (IF 98.4) Pub Date : 2025-05-21
Veronika J Wirtz, Hans V Hogerzeil, Andrew L GrayNo Abstract
-
Deterioration of health outcomes in Gaza: 19 months of protracted conflict Lancet (IF 98.4) Pub Date : 2025-05-22
Laura Paris, Ghada Al-Jadba, Wafaa Zeidan, Paul Spiegel, Zoheir Elkhatib, Rami Habash, Sanaa Al Najjar, Haya Khammash, Shatha Albeik, Tamer Shaer, Mohannad Ramadan, Seita AkihiroNo Abstract
-
ACURATE neo2 valve versus commercially available transcatheter heart valves in patients with severe aortic stenosis (ACURATE IDE): a multicentre, randomised, controlled, non-inferiority trial Lancet (IF 98.4) Pub Date : 2025-05-21
Raj R Makkar, Ravi K Ramana, Eric Gnall, Basel Ramlawi, Wen Cheng, Pantelis Diamantouros, Srinivasa Potluri, Neal Kleinman, Aakriti Gupta, Tarun Chakravarty, Sanjay Samy, Andrew Rassi, Vivek Rajagopal, Steven Yakubov, Paul Sorajja, Dhairya Patel, Santiago Garcia, Pradeep Yadav, Vinod Thourani, John Wang, Michael J ReardonBackgroundACURATE neo2 is an open-cell, supra-annular, self-expanding transcatheter heart valve that is commercially available in over 50 countries but has not previously been evaluated in a randomised trial. ACURATE-IDE aimed to prospectively evaluate the safety and efficacy of transcatheter aortic valve replacement (TAVR) with the ACURATE neo2 valve compared with commercially available valves for
-
Moving the dial on diagnostics: an update from the Lancet Commission on diagnostics Lancet (IF 98.4) Pub Date : 2025-05-20
Susan Horton, Michael L Wilson, Annie N Y Cheung, Kristen DeStigter, Mikashmi Kohli, Shahin Sayed, Lee F Schroeder, Richard Sullivan, Bien-Soo Tan, Millicent Alooh, Bernice Dahn, Lluis Donoso-Bach, Patricia J Garcia, Sarwat Hussain, Kekeletso Kao, Lai-Meng Looi, Madhukar Pai, Mario Plebani, Yenew Kebede Tebeje, Grace Umutesi, Kenneth A FlemingThe Lancet Commission on diagnostics made recommendations for ten topics: national strategy (including national essential diagnostics lists), access in primary care, workforce, regulatory framework, national financing, affordability, appropriate use of technology, needs in conflict or fragile situations, advocacy, and an international alliance with oversight capabilities. Since 2021, progress in these
-
Comparison of supplemental breast cancer imaging techniques—interim results from the BRAID randomised controlled trial Lancet (IF 98.4) Pub Date : 2025-05-21
Prof Fiona J Gilbert MBChB FRCR, Nicholas R Payne PhD, Iris Allajbeu MD, Lim Yit MBChB, Sarah Vinnicombe MBChB FRCR, Iain Lyburn MBChB, Nisha Sharma MBChB, Will Teh MBChB, Jonathan James MBChB, Archana Seth MBChB, Tamara Suaris MBChB, Reena Aggarwal MBChB, Miaad Al-Attar MBChB, Sarah Savaridas MBChB, Prof Antonis Antoniou MBChB PhD, Prof Paul Pharoah MBChB PhD, Prof Stephen Duffy MScIt is not known which supplemental imaging technique is most beneficial for women with dense breasts attending breast screening. This study compares abbreviated MRI, automated whole breast ultrasound (ABUS), and contrast-enhanced mammography versus standard of care in women with dense breasts and a negative mammogram. We report on interim results from the first round of supplemental imaging.
-
Breast cancer screening at a crossroads: supplemental imaging for dense breasts Lancet (IF 98.4) Pub Date : 2025-05-21
Nehmat HoussamiNo Abstract
-
Safety and efficacy of low-intensity versus standard monitoring following intravenous thrombolytic treatment in patients with acute ischaemic stroke (OPTIMISTmain): an international, pragmatic, stepped-wedge, cluster-randomised, controlled non-inferiority trial Lancet (IF 98.4) Pub Date : 2025-05-21
Prof Craig S Anderson MD PhD, Debbie Summers MSN, Menglu Ouyang PhD, Prof Yi Sui MD PhD, Brenda Johnson DNP, Prof Laurent Billot MRes, Alejandra Malavera MD, Roland Faigle MD PhD, Prof Paula Muñoz-Venturelli MD PhD, Diana Day MSc, Xiaoqiu Liu PhD, Qiang Li MBiostat, Prof Lili Song MD PhD, Prof Thompson G Robinson MD, Francisca González MPH, Francisca Urrutia-Goldsack MSc, Michael Iacobelli MPH, MichelleThe universally accepted best practice protocol for monitoring patients who receive intravenous thrombolysis for acute ischaemic stroke was established in the 1990s. However, the protocol is burdensome for nurses, disrupts the sleep of patients, and is potentially less relevant in patients at low risk of symptomatic intracerebral haemorrhage. We aimed to assess whether implementing a low-intensity
-
A new definition of human health is needed to better implement One Health Lancet (IF 98.4) Pub Date : 2025-05-19
Thierry Lefrançois, Jean-Luc Angot, Brigitte Autran, Salome A Bukachi, Elisabeth Claverie de Saint-Martin, Patrick Giraudoux, Estelle Lefrançois, Bruno Lina, Khuat Thi Hai Oanh, David O Obura, Jean-François DelfraissyNo Abstract
-
A wake-up call: the second Commission on adolescent health Lancet (IF 98.4) Pub Date : 2025-05-20
The LancetNo Abstract
-
The missing link in the NCD agenda: girls and young women remain overlooked Lancet (IF 98.4) Pub Date : 2025-05-20
Hamaiyal Sana, Marie Hauerslev, Muhammad Samsoor Zarak, Kasisomayajula ViswanathNo Abstract
-
A call to action: the second Lancet Commission on adolescent health and wellbeing Lancet (IF 98.4) Pub Date : 2025-05-20
Prof Sarah Baird PhD, Shakira Choonara PhD, Prof Peter S Azzopardi PhD, Prerna Banati PhD, Prof Judith Bessant PhD, Olivia Biermann PhD, Prof Anthony Capon PhD, Mariam Claeson MD, Prof Pamela Y Collins MD, Prof Nicole De Wet-Billings PhD, Surabhi Dogra MA, Yanhui Dong PhD, Kate L Francis MBiostat, Luwam T Gebrekristos MPH, Allison K Groves PhD, Simon I Hay DSc, David Imbago-Jácome MD, Aaron P JenkinsSection snippets Executive summaryAdolescents are the future leaders of our world. Ensuring their health and wellbeing—now and in the future—is one of the strongest mechanisms available to safeguard the collective future of humanity and to secure a more just society and a healthier and more productive planet. Investments in the current generation of 10–24-year-olds will reap a triple dividend, with
-
Investing in adolescent health and wellbeing to secure sustainable progress Lancet (IF 98.4) Pub Date : 2025-05-20
Tedros Adhanom GhebreyesusNo Abstract
-
Sarah Baird: understanding, action, and optimism Lancet (IF 98.4) Pub Date : 2025-05-20
Niall BoyceNo Abstract
-
Starvation as a weapon of war in Gaza: violation of international law Lancet (IF 98.4) Pub Date : 2025-05-20
Yara Ashour, Abdallah Abu-Jlambo, Samer AbuzerrNo Abstract
-
A pillar of Brazilian public health: Fiocruz at 125 Lancet (IF 98.4) Pub Date : 2025-05-19
Lise AlvesNo Abstract
-
Dietary energy in balance: time for an update of energy requirements Lancet (IF 98.4) Pub Date : 2025-05-16
L M Neufeld, C U LoechlNo Abstract
-
The potential impact of the Trump administration policies on health research in the USA Lancet (IF 98.4) Pub Date : 2025-05-16
Steven H Woolf, Sandro Galea, David R WilliamsNo Abstract
-
Ending nuclear weapons, before they end us Lancet (IF 98.4) Pub Date : 2025-05-16
Kamran Abbasi, Parveen Ali, Virginia Barbour, Marion Birch, Inga Blum, Peter Doherty, Andy Haines, Ira Helfand, Richard Horton, Kati Juva, Jose F Lapena, Robert Mash, Olga Mironova, Arun Mitra, Carlos Monteiro, Elena N Naumova, David Onazi, Tilman Ruff, Peush Sahni, James Tumwine, Chris ZielinskiNo Abstract
Copyright © 2014-2025 北京衮雪科技有限公司 All Rights Reserved
京ICP备11026495号-2
京公网安备 11010802027423号
京公网安备 11010802027423号